Ovid Therapeutics Files 8-K on Shareholder Nominations

Ticker: OVID · Form: 8-K · Filed: 2025-05-02T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-nomination, sec-filing

TL;DR

Ovid Therapeutics filed an 8-K regarding shareholder nominations for board seats.

AI Summary

Ovid Therapeutics Inc. filed an 8-K on May 2, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing indicates that the company is providing information related to shareholder proposals for its upcoming meeting.

Why It Matters

This filing is important for shareholders as it outlines the process and details regarding nominations for the board of directors, impacting corporate governance.

Risk Assessment

Risk Level: low — This is a routine procedural filing related to corporate governance and shareholder nominations, not indicating any immediate financial or operational risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on shareholder nominations pursuant to Exchange Act Rule 14a-11.

What is the exact date of the earliest event reported in this filing?

The earliest event reported in this filing is dated May 1, 2025.

What is the filing date of this 8-K report?

This 8-K report was filed on May 2, 2025.

What is the company's exact name as specified in its charter?

The company's exact name as specified in its charter is Ovid Therapeutics Inc.

Under which section of the Securities Exchange Act is this report filed?

This Current Report is filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0001193125-25-111633.txt : 20250502 0001193125-25-111633.hdr.sgml : 20250502 20250502161440 ACCESSION NUMBER: 0001193125-25-111633 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250501 ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 FILED AS OF DATE: 20250502 DATE AS OF CHANGE: 20250502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 25908701 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 8-K 1 d830663d8k.htm 8-K 8-K false 0001636651 0001636651 2025-05-01 2025-05-01     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025     OVID THERAPEUTICS INC. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-38085   46-5270895 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   441 Ninth Avenue , 14th Floor New York , New York   10001 (Address of Principal Executive Offices)   (Zip Code) Registrant’s Telephone Number, Including Area Code: 646 - 661-7661 Not Applicable (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock par value $0.001 per share   OVID   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.08 Shareholder Director Nominations. On May 1, 2025, the Board of Directors of Ovid Therapeutics Inc. (the “Company”) established July 9, 2025 as the date of the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). The time and location of the 2025 Annual Meeting will be set forth in the Company’s definitive proxy statement for the 2025 Annual Meeting to be filed with the Securities and Exchange Commission (the “SEC”). The record date for determining stockholders entitled to notice of, and to vote at, the 2025 Annual Meeting will be the close of busi

View on Read The Filing